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ABSTRACT 
Influenza is responsible for significant morbidity after transplantation. We evaluated Th1/Th2 cytokines and IL-10 levels 
during influenza infection in the post-transplant setting.  Sera from 277 transplant recipients were analyzed at influenza 
diagnosis and 28 days later for IFN-γ, IL-4, IL-13 and IL-10. IL-13 levels were associated with protection against 
pneumonia and ICU admission, whereas the IFN-γ/IL-13 ratio and IL-10 levels were associated with an increased risk of 
pneumonia and ICU admission. This association was independent of viral load. A skewing of immune responses towards 
Th2 in transplant patients appears to confer protection from severe influenza infection, independently of viral load. 
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BACKGROUND 
Influenza virus infection is responsible for significant morbidity and mortality in solid organ transplant (SOT) and 
hematopoietic stem cell transplant (HSCT) recipients[1]. Despite yearly immunization, a significant proportion of transplant 
patients develop influenza[1], which is likely related to the underlying immunosuppression, and the discordance between 
circulating influenza strains and those included in annual vaccine formulations. 
Most transplant patients who develop influenza infection will recover fully, although 20-30% develop complications 
including pneumonia, possibly requiring intensive care unit (ICU) admission or mechanical ventilation, and death[1]. The 
role that the host immune response plays in the development or prevention of these complications has not been well 
understood in transplant patients. Also, there is a need for reliable biomarkers to identify transplant patients most at risk 
for severe infection. 
T-helper (Th) immunity is commonly divided into Th1 and Th2. During an infection, Th1 immunity is characterized by 
induction of opsonizing antibodies, intense phagocytic activity and pathogen clearance, as well as facilitating cell-
mediated immunity (CMI) against intracellular microbes via macrophages and CD8 T-cell activation[2, 3]. On the other 
hand, Th2 immunity assists in the resolution of inflammation and development of humoral immunity against extracellular 
pathogens[2]. Therefore, the delicate balance between Th1 and Th2 immunity contributes to resolution of infection. The 
absence of data in the immunocompromised population, combined with the evidence of increased influenza severity in 
transplant patients, underscores the need to better understand Th1/Th2 responses and IL-10 levels in natural influenza 
infection, and to evaluate whether cytokine levels can be clinically informative or predictive. Based on prior studies in 
immunocompetent patients demonstrating worse outcomes of influenza in those with decreased Th2 cytokines and/or 
elevated IL-10 levels[4-12], we hypothesized that an increased Th1/Th2 ratio and increased IL-10 levels were associated 
with influenza severity after transplant. 
 
METHODS 
Study Design. This study was a sub-study of a multicenter prospective observational study designed as previously 
described[1].  Briefly, 20 centers in Spain, Canada and United States identified through the American Society of 
Transplantation Infectious Diseases Community of Practice participated. Local investigators prospectively identified 
transplant patients with influenza infection. The trial was registered under clinicaltrials.gov (NCT01256255). Inclusion 
criteria were 1) pediatric or adult SOT or HSCT recipient, 2) microbiologically confirmed influenza by reverse-transcription 
polymerase chain reaction during the 2010-15 influenza seasons using a nasopharyngeal (NP) swab or bronchoalveolar 
lavage specimen, 3) informed consent, and 4) available serum specimen at influenza diagnosis. Detailed clinical 
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information was gathered and patients were followed for six months following influenza diagnosis. The primary and 
secondary outcomes were pneumonia and ICU admission, respectively.  
Cytokine Analysis. Blood was taken at enrollment and 28 days later. Blood was centrifuged for 10 minutes at 2,000x g, 
and collected serum was stored at -80ºC. IFN-γ was selected as the Th1-representative cytokine, IL-4 and IL-13 as Th2-
representative cytokines, and IL-10 as an immunoregulatory cytokine. Specimens with insufficient sample volume for 
accurate cytokine measurement were excluded (n=14). Cytokine analysis was performed using the Luminex™ 100 
system (Luminex, Austin, TX, USA) by Eve Technologies Corp. (Calgary, AB, Canada). All analyses were run in duplicate. 
The quantification limit (QL) was 0.01pg/mL for IFN-γ, IL-10 and IL-13, and 0.01ng/ml for IL-4. For the purposes of 
statistical analysis, values below the QL were given a value of half the QL. 
Viral Load Analysis. NP swabs were performed at day 0, 3, 6,11, 18 and 28 after enrollment for viral load (VL) 
quantification in influenza A-infected patients, as previously described[1].  
Statistical Analysis. The Th1/Th2 ratio and IL-10 levels were compared between patients with or without pneumonia or 
ICU admission using Mann-Whitney U-test. Post-hoc analysis compared IFN-γ and IL-13 levels between patients with or 
without complications using Mann-Whitney U-test, and correlated VL half-life and cytokine values using Spearman 
correlation. To adjust for multiple comparisons, Bonferroni adjustment was performed and p-values <0.0125 were 
considered significant.  Statistics were performed using SPSS version 23.0 (IBM Corp., Armonk, NY). Figures were made 
using GraphPad 7.0 (LaJolla, CA). 
 
RESULTS 
Demographics 
Of the 616 patients with influenza infection included in the overall cohort, 277 (45.0%) had sera available at enrollment.  
Of these, 229 also had day 28 sera available.  The clinical and epidemiologic characteristics of our subcohort were similar 
than those of main cohort[1] and are shown in Table 1. All patients were treated with neuraminidase inhibitors. 
 
Cytokine levels at enrollment and at day 28 
Cytokine values were analyzed at enrollment and day 28. All 277 patients had quantifiable IFN-γ (median 0.82pg/mL [IQR 
0.64-1.42]) and IL-13 (median 4.86pg/mL [IQR 1.23-33.07]) at enrollment (Supplementary Figure 1A-B). IL-10 was 
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quantifiable in 92.1% (255/274) of patients at enrollment, with a median value of 1.39pg/mL (IQR 0.05-5.92) 
(Supplementary Figure 1C) whereas IL-4 at enrollment was quantifiable in 27.1% (75/269) with the median value below 
the QL. At day 28, all 229 patients had quantifiable IFN-γ (median 0.74pg/mL [IQR 0.61-1.01]) and IL-13 (median 
6.26pg/mL [IQR 1.25-33.15]). IL-10 was quantifiable in 86.8% (196/228), with a median value of 0.07pg/mL (IQR 0.01-
1.47), whereas IL-4 was quantifiable in only 21.6% (49/227) with a median value below the QL (Supplementary Figure 1A-
C).  
Role of immunosuppression and immunization status on cytokine levels are described in Supplementary results. 
 
Th1/Th2 ratio 
Based on the hypothesis that the balance of Th1 vs Th2 responses is important in influenza pathogenesis, we analyzed 
the IFN-γ/IL-13 ratio since both cytokines were detectable in all patients.  The range of Th1/Th2 ratios at baseline is 
shown in Supplementary Figure 1D (median 0.26; IQR 0.06-0.75). Significant variation was observed with some patients 
showing a skewing towards a Th1 response and others towards a Th2 response.  By day 28, the median Th1/Th2 ratio 
was slightly lower than at baseline (median 0.18; IQR 0.05-0.61) (Supplementary Figure 1D).  
 
Association of cytokines and Th1/Th2 ratio with disease severity 
We evaluated the association of cytokine levels, as well as Th1/Th2 ratio, with influenza severity, defined as the presence 
of pneumonia at presentation (n=62) or the need for ICU admission (n=28). First we analyzed day 0 and day 28 IFN-γ and 
IL-13 values in patients with and without pneumonia and ICU admission. At both time points, we found no differences in 
IFN-γ levels between patients who did or did not have either pneumonia or ICU admission (Supplementary Figure 2A-B). 
In contrast, IL-13 levels at day 0 and day 28 were lower in patients with pneumonia and in those with ICU admission, 
although this was only significant at day 28 (Supplementary Figure 2C-D). 
We then evaluated the Th1/Th2 profile (IFN-γ/IL-13 ratio) and observed that a lower Th1/Th2 ratio at day 0 was 
associated with decreased incidence of ICU admission, whereas a lower Th1/Th2 ratio at day 28 was associated with a 
decreased incidence of both pneumonia and ICU admission (Figure 1A-B).  
We assessed whether IL-10 levels were associated with disease severity by comparing levels between patients with and 
without severe influenza. Higher levels of IL-10 at day 0 were associated with an increased risk of ICU admission, and 
higher levels of IL-10 at day 28 were associated with an increased risk of both pneumonia and ICU admission (Figure 1C-
D).  
Mortality data related to cytokine levels are described in Supplementary results. 
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Viral load  
VL was tested in the 187 patients. Median VL at influenza infection onset was 4.25log copies/ml (IQR 3.05-5.52log 
copies/ml) and median time to clearance was 6 days (IQR 3-11). There was no correlation between baseline VL (p=NS for 
all comparisons), viral clearance kinetics (as determined by VL half-life) and either Th1/Th2 ratio (Correlation Coefficient: 
0.071; p=0.454) or IL-10 levels (Correlation Coefficient: -0.108; p=0.259) at day 0. 
 
DISCUSSION 
This study evaluates Th1/Th2 responses during influenza infection in a large cohort of transplant patients. The delicate 
balance of Th1/Th2 responses are likely to play an important role in the pathogenesis and recovery from infections[2, 3]. 
The main finding of our study was that patients with immune responses directed towards Th2 had a lower incidence of 
pneumonia or ICU admission, as reflected by IL-13 levels but also by the IFN-γ/IL-13 ratio. This association was 
independent of baseline VL.  Both IL-4 and IL-13 are prototypical Th2 cytokines that stimulate the humoral immune 
responses during an infection[2]. IL-4 was undetectable in most patients of our cohort, confirming previous findings in 
influenza-infected immunocompetent children[8], and thus not used for group comparisons. The protective effect of Th2 
cytokines during influenza infection is debated, some studies in immunocompetent cohorts having shown a protective 
effect[7, 11], others a deleterious effect[5, 6] or no association between Th2 cytokines and influenza severity[4].  
Differences in studies could be related to different cytokine assays, use of antivirals, different times between symptom 
onset and blood collection, or the presence of a possible viral or bacterial co-infection[4-7, 11]. 
IFN-γ was quantifiable in all our patients, although levels were lower than in influenza-infected immunocompetent 
cohorts[4-6, 9, 10, 13]. Previously, studies have shown that IFN-γ levels are higher in influenza-infected patients 
compared to controls[4, 10, 13]. Surprisingly, the interpatient variation in IFN-γ levels was low and levels did not correlate 
with influenza severity, which is consistent with most studies performed in immunocompetent cohorts[5, 9, 13]. The fact 
that IFN-γ seems protective in some series[7, 10, 11] and deleterious in others[6] is likely related to its typical 
proinflammatory profile which increases pathogen clearance but also increases the risk of immunopathology[3]. These 
differences might also be explained by the fact that some studies only investigated H1N1/pdm09-infected patients, 
whereas others included H3N2- or influenza B-infected individuals, the latter being associated with higher IFN-γ levels[9].   
The other important finding of our study was the relationship between elevated IL-10 levels and pneumonia, ICU 
admission, and late mortality. IL-10 is produced by many cell types of the innate and adaptive immune system and is the 
most potent anti-inflammatory cytokine[14]. By inhibiting macrophages, Th1 and natural killer cells, IL-10 reduces tissue 
damage but also impairs pathogen clearance in bacterial, viral and protozoal infections[14]. Thus, IL-10 is frequently 
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considered a double-edged sword. When compared to healthy controls, IL-10 levels were increased in influenza-infected 
patients[4, 10, 13]. The relationship between IL-10 levels and influenza severity has been extensively studied in 
immunocompetent populations. Although few studies were unable to demonstrate any relationship[7, 13], most have 
associated IL-10 levels with influenza severity[4, 8-10, 12], including pneumonia and ICU admission[5, 6, 9]. Although 
those studies were performed on immunocompetent cohorts, results are consistent with our data showing that IL-10 levels 
are higher in patients with pneumonia and ICU admission, especially evident at day 28, despite levels in our cohort being 
lower than in influenza-infected immunocompetent individuals[4-6, 8-10]. The strong anti-inflammatory effects of IL-10 
leading to reduced pathogen clearance could explain why elevated levels were associated with influenza severity. 
Alternatively, vaccine studies have shown dysregulated IL-10 production in elderly vaccine non-responders[15]; similar to 
older adults, transplant patients have impaired CMI and a dysregulated IL-10 production during natural infection could 
impair development of immunity, therefore increasing disease severity. 
This study has some limitations. First, this is a substudy of a larger study; however, it is still the largest study of immune 
response to influenza after transplantation. Second, although there was heterogeneity in type of transplant, there were no 
significant difference in cytokine levels between HSCT and SOT patients, nor between organ transplants. Also, due to the 
study design, it is not possible to confirm whether cytokines determined at influenza diagnosis are the cause or the 
consequence of influenza severity. Finally, IL-4 levels were undetectable in most patients, and therefore this cytokine 
could not be used for Th1/Th2 ratio. 
In conclusion, this is the first study examining serum cytokines during natural influenza infection in a large cohort of 
transplant patients. Despite levels of cytokines significantly lower than in immunocompetent cohorts, our data showed that 
an immune response directed towards Th2 was associated with decreased influenza severity and IL-10 was associated 
with increased influenza severity. These associations were independent of VL, highlighting that the nature of the immune 
response strongly contributes to disease severity. Further studies are needed in immunosuppressed cohorts to evaluate 
whether these cytokines could have clinical utility as biomarkers to predict influenza severity or to help guide modification 
of immunosuppression in patients with severe influenza. 
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Supplementary results 
 
Role of immunosuppression on cytokine levels 
Among our SOT patients, there was no significance difference in IFN-γ, IL-10, IL-13 or IFN- γ/IL-13 ratio at day 0 and day 
28 between the 187 patients treated with calcineurin inhibitors but no mTOR inhibitors and the 15 patients treated with 
mTor inhibitors but no calcineurin inhibitors (data not shown). 
 
Association between cytokine levels and mortality 
There was no association between IFN-γ, IL-13 or IFN-γ/IL-13 ratio at day 0 with mortality at day 28 (data not shown). 
There was no association between IL-10 levels at day 0 with mortality at day 28. However, IL-10 levels were higher both 
at day 0 (6.18pg/ml [IQR 1.33-35.17] vs 1.29pg/ml [IQR 0.04-5.70]; p=0.004) and day 28 (3.13pg/ml [IQR 0.54-32.76] vs 
0.05pg/ml [IQR 0.01-1.42]; p<0.001) among non-survivors at 6 months. 
 
Role of immunization status on cytokine levels 
There was no difference in IFN-γ, IL-13 or IFN-γ/IL-13 ratio at day 0 and day 28 between patients who did or did not 
receive the influenza vaccine the season they became infected. Moreover, IL-10 levels at day 0 did not significantly differ 
between the two groups (data not shown). However, median IL-10 levels at day 28 were significantly lower in immunized 
patients (0.03pg/ml [IQR 0.01-0.93] vs 0.2pg/ml [IQR 0.03-2.40]; p=0.002).  
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Table 1. Demographics of patients infected with influenza. 
Baseline demographics n=277 
 
Median age (IQR), yrs 56.0 (44.0-65.0) 
 
Male/Female ratio 1.47 / 1 
 
Median time since transplant (IQR), yrs 3.09 (0.67-9.44) 
Transplantation 
 
 
Solid Organ Transplantation, n (%) 224 (80.9)# 
  
kidney 135 (60.2) 
  
liver 34 (15.2) 
  
lung 30 (13.4) 
  
heart 23 (10.3) 
  
small bowel 1 (0.4) 
  
pancreatic islets 1 (0.4) 
 
Hematopoietic Stem Cell Transplantation, n(%) 54 (19.5) 
  
allogeneic 40 (74.1) 
  
autologous 14 (25.9) 
Influenza infection 
 
 
Immunization for current influenza season, n (%) 170 (67%)* 
 
Influenza Type 
 
  
Influenza A 187 (67.5) 
   
H1 80 (42.8) 
   
H3 82 (43.9) 
   
unspecified 23 (12.3) 
  
Influenza B 52 (18.8) 
  
unknown 35 (12.6) 
 
Complications 
 
  
Pneumonia 62 (22.4) 
    ICU admission 28 (10.1) 
  Death at 28 days 9 (3.2) 
  Death at 6 months 18 (6.5) 
*information was not available in 23 patients. #: one patient had both allogenic stem cell and liver transplantation. 
IQR: interquartile range; ICU: intensive care unit.  
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